HONG KONG, Sept. 13, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) today announced the presentation of positive overall survival (OS) results from the randomized, double-blind, multicenter, registrational Phase III HARMONi-2 study (AK112-303) at the 2026 World Conference on Lung Cancer...
Hence then, the article about ivonescimab versus pembrolizumab in first line pd l1 positive nsclc positive overall survival results from harmoni 2 presented at wclc 2026 was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Ivonescimab Versus Pembrolizumab in First-Line PD-L1-Positive NSCLC: Positive Overall Survival Results from HARMONi-2 Presented at WCLC 2026 )
Also on site :
- ‘I Play Rocky’ Premieres at TIFF: A Movie About a Best Picture Winner That’s a Best Picture Contender?
- 2006 No. 1 Hit, Written by a 15-Year-Old High School Freshman, Ranks as One of the ‘Greatest Country Songs of All Time’
- Mahershala Ali Reveals He Was “Yearning” to Perform Action On-Screen Before Filming ‘Your Mother, Your Mother, Your Mother’